Home / Market News / $SYRE
benzinga Corporate Catalyst Impact 65/100 ● neutral

UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

Oct 12, 2026, 1:39 PM UTC · Primary ticker $SYRE

UBS has initiated coverage on Spyre Therapeutics (SYRE) with a 'Buy' rating and a price target of $120. This analyst coverage and positive rating could provide a significant boost to investor confidence and potentially the stock price.

UBS analyst Alice Nettleton has initiated coverage on Spyre Therapeutics (SYRE) with a 'Buy' rating and a $120 price target. This is a significant event for SYRE as new analyst coverage, especially with a positive rating and a substantial price target, often brings increased visibility and investor interest to a stock. For traders, this could lead to short-term upward price momentum as the market reacts to the news. In the long term, sustained positive analyst sentiment and execution on the company's part would be crucial for the stock to reach and maintain the target price. The key opportunity for traders is to capitalize on the immediate positive sentiment, while the risk lies in the possibility that the market has already priced in such expectations or that future company performance doesn't align with analyst projections.

$SYRE positive New 'Buy' rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.